Related Experiment Video
Updated: May 4, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Biomarkers in atrial fibrillation: an overview
J A Vílchez1, V Roldán, D Hernández-Romero
1Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Murcia, Spain; Department of Clinical Analysis, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Murcia, Spain.
Insights
Biomarkers can improve risk assessment for atrial fibrillation (AF) patients, identifying those at higher risk of stroke. This review explores current biomarkers and their role in predicting adverse events in AF.
Area of Science:
- Cardiology
- Biomarker Research
- Atrial Fibrillation Pathophysiology
Background:
- Atrial fibrillation (AF) significantly increases stroke and death risk, exacerbated by cardiovascular risk factors.
- AF pathophysiology involves inflammation, structural remodeling, apoptosis, and fibrosis, leading to a prothrombotic state.
- Current clinical risk scores for oral anticoagulant therapy in AF have limited predictive accuracy for thromboembolic events.
Purpose of the Study:
- To review published data on biomarkers studied in atrial fibrillation.
- To focus on data from randomized prospective clinical trials and large community-based cohorts.
- To assess the application of biomarkers in predicting prognosis and improving risk stratification in AF.
Main Methods:
- Systematic review of literature on AF biomarkers.
- Analysis of data from prospective clinical trials and community cohorts.
- Evaluation of biomarker utility in risk stratification schemes for AF.
Main Results:
- Biomarkers, including those in blood, urine, and imaging, offer potential to enhance understanding of AF pathophysiology.
- Biomarkers show promise in identifying 'high risk' patients beyond traditional clinical scores.
- The review synthesizes evidence on biomarker application for AF prognosis and risk assessment.
Conclusions:
- Biomarkers are crucial for improving the identification and management of high-risk individuals with atrial fibrillation.
- Further research and validation of biomarkers are needed to refine prognostic accuracy and clinical decision-making in AF.
- Biomarker integration into risk stratification schemes can optimize oral anticoagulant therapy and patient outcomes in AF.
Abstract:
Atrial fibrillation (AF) confers a raised risk of stroke and death, and this risk of adverse events is increased by the coexistence of other cardiovascular risk factors. The pathophysiology of AF is complex, involving the role of inflammation, structural remodelling with apoptosis, inflammation or fibrosis. These changes confer a prothrombotic or hypercoagulable state in this arrhythmia. Despite being easy to use for decision-making concerning oral anticoagulant therapy in AF, clinical risk scores used for stratification have shown modest capability in predicting thromboembolic events, and biomarkers may improve our identification of 'high risk' patients. Biomarkers, whether measured in the peripheral blood, urine or imaging-based may improve our knowledge of the pathophysiology of AF. Importantly these biomarkers could help in the assessment of AF prognosis. The aim of this review was to summarise the published data about biomarkers studied in AF, with focus on data from randomised prospective clinical trials and large community-based cohorts. We will also review the application of these biomarkers to prognosis on the main schemes used to help stratify risk in AF.
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies
Dysrhythmias III: Characteristics of Dysrhythmias

